Tripos is a recognized global leader in the design, development and marketing of innovative scientific software products and services that enable life science researchers to improve the efficiency of their molecular discovery efforts. Established in 1979, Tripos was the first company to bring computer aided, scientific computational drug discovery capabilities to the pharmaceutical industry, and today helps a broad range of pharmaceutical companies and research facilities successfully accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, chemical, research, food, flavoring and fragrance markets. Tripos is wholly owned by Vector Capital, a San Francisco-based private equity boutique specializing in buyouts, spinouts and recapitalizations of established technology businesses.
Tripos is widely respected for the strength of its scientists, and their scientific firsts. The Company continues its long tradition of being first to market with breakthrough solutions that support the research efforts of a spectrum of organizations, from large, established global firms, to emerging startups. Headquartered in St. Louis, Missouri, Tripos serves more than 1,000 customers in more than 46 countries.
